Literature DB >> 17548573

Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis?

Robert Zivadinov1.   

Abstract

MRI is the most important paraclinical measure for assessing and monitoring the pathologic changes implicated in the onset and progression of multiple sclerosis (MS). Conventional MRI sequences, such as T1-weighted gadolinium-enhanced and spin-echo T2-weighted imaging, are unable to provide full details about the degree of inflammation and underlying neurodegenerative changes. Newer nonconventional MRI techniques have the potential to detect clinical impairment, disease progression, accumulation of disability, and the neuroprotective effects of treatment. Unenhanced T1-weighted imaging can reveal hypointense black holes, a measure of chronic neurodegeneration. Two- and three-dimensional fluid-attenuated inversion recovery sequences allow better identification of cortical lesions. Ultrahigh-field strength MRI has the potential to detect subpial cortical and deep gray matter lesions. Magnetization transfer imaging is increasingly used to characterize the evolution of MS lesions and normal-appearing brain tissue. Evidence suggests that the dynamics of magnetization transfer changes correlate with the extent of demyelination and remyelination. Magnetic resonance spectroscopy, which provides details on tissue biochemistry, metabolism, and function, also has the capacity to reveal neuroprotective mechanisms. By measuring the motion of water, diffusion imaging can provide information about the orientation, size, and geometry of tissue damage in white and gray matter. Functional MRI may help clarify the brain's plasticity-dependent compensatory mechanisms in patients with MS. High-resolution microautoradiography and new contrast agents are proving to be sensitive means for characterizing molecular markers of disease activity, such as activated microglia and macrophages. Optical coherence tomography, a new research technique, makes it possible to investigate relevant physiologic systems that provide accurate measures of tissue changes secondary to the MS disease process. Although detecting the status of neuronal integrity using MRI techniques continues to improve, a "gold standard" model remains to be established.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17548573     DOI: 10.1212/01.wnl.0000275236.51129.d2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Neuroprotection and neuroregeneration in multiple sclerosis.

Authors:  Martin Stangel
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 2.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

3.  Chronic T2 Lesions in Multiple Sclerosis are Heterogeneous Regarding Phase MR Imaging.

Authors:  S Siemonsen; K L Young; M Bester; J Sedlacik; C Heesen; J Fiehler; J-P Stellmann
Journal:  Clin Neuroradiol       Date:  2015-04-18       Impact factor: 3.649

4.  Composite MRI scores improve correlation with EDSS in multiple sclerosis.

Authors:  A H Poonawalla; S Datta; V Juneja; F Nelson; J S Wolinsky; G Cutter; P A Narayana
Journal:  Mult Scler       Date:  2010-09       Impact factor: 6.312

5.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

6.  A novel approach with "skeletonised MTR" measures tract-specific microstructural changes in early primary-progressive MS.

Authors:  Benedetta Bodini; Mara Cercignani; Ahmed Toosy; Nicola De Stefano; David H Miller; Alan J Thompson; Olga Ciccarelli
Journal:  Hum Brain Mapp       Date:  2013-04-24       Impact factor: 5.038

Review 7.  Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Authors:  Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; Omar Khan; Hans-Peter Hartung; Olaf Stüve
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis.

Authors:  Shumita Roy; Ralph H B Benedict; Allison S Drake; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 5.749

Review 9.  The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome.

Authors:  Robert Zivadinov; Milena Stosic; Jennifer L Cox; Deepa P Ramasamy; Michael G Dwyer
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

10.  Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging.

Authors:  E Mark Haacke; Malek Makki; Yulin Ge; Megha Maheshwari; Vivek Sehgal; Jiani Hu; Madeswaran Selvan; Zhen Wu; Zahid Latif; Yang Xuan; Omar Khan; James Garbern; Robert I Grossman
Journal:  J Magn Reson Imaging       Date:  2009-03       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.